Sun Pharma launches novel drug Kapspargo Sprinkle in the United States of America

Sun Pharmaceutical Industries Ltd. has launched Kapspargo Sprinkle (metoprolol succinate) extended-release capsules in the United States of America, for the treatment of hypertension (to lower blood pressure), angina pectoris (chest pain), and heart failure (to reduce the risk of cardiovascular mortality and heart-failure hospitalization in patients with heart failure). Kapspargo Sprinkle, a USFDA approved, novel, patented formulation of metoprolol succinate, is the first and only extended-release sprinkle formulation of this beta1-selective adrenoreceptor blocking agent (beta-blocker). It is covered by United States patent numbers 9,504,655 and 9,700,530, expiring Jul 09, 2035. Kapspargo Sprinkle pellets can be sprinkled over soft food (such as applesauce, yogurt, or pudding) or administered via a nasogastric tube, and are designed to facilitate long-term, once-daily administration, particularly for patients who have difficulty swallowing.